Amy Atkins
Nurse Practitioner · Tuscaloosa, ALNPI 1689819799
Payments from drug & device makers
Across 148 payments — averaging $15.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$669
- Lilly USA, LLC$459
- AbbVie$281
- Exact Sciences$169
- Abbott$88
- Bayer$74
- plus $576 from 18 others
What the payments were for
- Food & beverage$2,316100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 55 | $669 |
| Lilly USA, LLC | 24 | $459 |
| AbbVie | 17 | $281 |
| Exact Sciences | 11 | $169 |
| Abbott | 4 | $88 |
| Bayer | 3 | $74 |
| Pfizer | 4 | $74 |
| Corium, LLC | 3 | $71 |
| Phathom Pharmaceuticals, Inc. | 4 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $45 |
| Boehringer Ingelheim | 3 | $44 |
| Merck | 3 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Johnson & Johnson | 1 | $24 |
| Genentech USA, Inc. | 2 | $23 |
| Almatica Pharma LLC | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Organogenesis Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Dexcom, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $15 |
How this compares
$2,316 in reported general payments places this provider in the 80th percentile of 1,505 nurse practitioner providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 73 | $108,617 |
| OzempicSemaglutide | 33 | $38,788 |
| Metformin Hcl | 14 | $74 |
| Ondansetron Hcl | 18 | $55 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $459 | $108,61773 claims |
| Novo NordiskOzempic | $669 | $38,78833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,505 nurse practitioner providers in Alabama.
Other nurse practitioner in Tuscaloosa
- Tyler KeenumTuscaloosa$10K
- James FenleyTuscaloosa$10K
- Linda CanterburyTuscaloosa$9K
- John ChambersTuscaloosa$8K
- Erin TannerAlabaster$141K
- Ardie Pack MabienMobile$126K
- Ginger McDanielBirmingham$27K
- Audrey MorganMontgomery$24K
- Hollie CrutchfieldDothan$22K
- Leah GravesBirmingham$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.